Cytek Biosciences Inc (CTKB)
Financial leverage ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 494,457 | 519,430 | 525,054 | 524,575 | 519,476 | 499,295 | 492,817 | 485,879 | 463,305 | 454,320 | 230,279 |
| Total stockholders’ equity | US$ in thousands | 393,064 | 415,524 | 424,179 | 423,460 | 425,546 | 416,509 | 411,129 | 407,442 | 405,385 | 403,195 | -10,985 |
| Financial leverage ratio | 1.26 | 1.25 | 1.24 | 1.24 | 1.22 | 1.20 | 1.20 | 1.19 | 1.14 | 1.13 | — |
December 31, 2023 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $494,457K ÷ $393,064K
= 1.26
The financial leverage ratio of Cytek Biosciences Inc has been gradually increasing over the past few quarters, indicating that the company is relying more on debt to finance its operations and growth. As of Dec 31, 2023, the financial leverage ratio stands at 1.26, the highest level in the provided data. This suggests that for every $1 of equity, Cytek Biosciences Inc has $1.26 of debt.
The trend of increasing financial leverage may be a strategic move to take advantage of low interest rates or to fund expansion projects. However, a higher financial leverage ratio also increases the company's financial risk, as it becomes more sensitive to changes in interest rates and may face challenges in meeting debt obligations during economic downturns.
It is important for investors and stakeholders to monitor Cytek Biosciences Inc's financial leverage ratio closely to ensure that the company is managing its debt levels prudently and maintaining a healthy balance between debt and equity in its capital structure.
Peer comparison
Dec 31, 2023